[A25-128] Trastuzumab deruxtecan (gastric or gastroesophageal junction adenocarcinoma) – Benefit assessment according to §35a Social Code Book V
Last updated 10.12.2025
Project no.:
A25-128
Commission:
Commission awarded on 30.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Drug Assessment
Topic:
Cancer
| Project no. | Title | Status |
|---|---|---|
| A25-54 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-115 | Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-07 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-08 | Trastuzumab deruxtecan (gastric cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-80 | Trastuzumab deruxtecan (breast cancer) – Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-81 | Trastuzumab deruxtecan (breast cancer, HER2+, at least 2 prior therapies) – Benefit assessment according to §35a Social Code Book V | Commission completed |